News

Atopic Eczema and the Filaggrin Story

The recent discovery that mutations within the filaggrin gene (FLG) are strongly associated with atopic eczema represents a very significant breakthrough in understanding the genetic basis of this common disorder.


 

Sara J. Brown, MBChB, BSc, MRCP, and Alan D. Irvine, MD, FRCPI

The discovery that null mutations in the filaggrin gene (FLG) are associated with atopic eczema represents the single most significant breakthrough in understanding the genetic basis of this complex disorder. The association has been replicated in multiple independent studies during the past 2 years with the use of various methodologies, from populations in Europe, the United States, and Japan. Filaggrin plays a key role in epidermal barrier function, and its association with atopic eczema emphasizes the importance of barrier dysfunction in eczema pathogenesis. This review aims to summarize the current state of knowledge regarding the role of FLG mutations in ichthyosis vulgaris, atopic eczema, and other skin disorders, with an emphasis on potential clinical applications. Further research is needed to clarify the precise role of filaggrin in skin and systemic atopic disease, to pave the way for novel therapeutic interventions.

*For a PDF of the full article, click on the link to the left of this introduction.

Recommended Reading

Tacrolimus Comes Out on Top for Treating Atopy
MDedge Dermatology
Long-Term Use of Tacrolimus for AD Flares Found to Reduce Relapse Risk
MDedge Dermatology
Web Use May Be Reason for Eczema Patient's Steroid Fear
MDedge Dermatology
Topical Therapy in Pediatric Atopic Dermatitis
MDedge Dermatology
Pediatric Atopic Dermatitis: The Importance of Food Allergens
MDedge Dermatology
Atopic Dermatitis: Systemic Immunosuppressive Therapy
MDedge Dermatology
Antimicrobial Peptides, Skin Infections, and Atopic Dermatitis
MDedge Dermatology
The Immune System and Atopic Dermatitis
MDedge Dermatology
The Effect of Ceramide-Containing Skin Care Products on Eczema Resolution Duration
MDedge Dermatology
A Single-Center, Double-Blind, Randomized Trial of the Atrophogenic Effects of Fluocinonide Cream 0.1% Versus Clobetasol Propionate Cream 0.05% in Participants With Corticosteroid-Responsive Dermatoses
MDedge Dermatology